# US 2014/0005217 A1 · Nalmefene for reduction of alcohol consumption in specific target populations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0005217 A1
- Document ID: US20140005217A1
- Status: Published application
- Kind: A1
- Application number: 13/928,332
- Filed: 2013-06-26
- Published: 2014-01-02
- Earliest claimed: 2012-06-27
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: Lars Torup; Afsaneh Abbariki; Anna Bladstrom; Christine Persson; Didier Meulien; Per Sorensen; Thomas Jon Jensen; Jette Buch Ostergaard
- Web page: https://patentgrep.com/patent/US20140005217A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/32: Alcohol-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.

## Claims

### Claim 1

A method of reducing alcohol consumption in a patient wherein said method comprises the following steps:
a identifying a patient i) who has a high DRL, and ii) who maintains a high DRL after an observation period following initial assessment, and
b) administering a therapeutically effective amount of nalmefene to the patient identified in step a), wherein said nalmefene is to be administered as-needed about 1-2 hours prior to the anticipated time of drinking.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said observation period following initial assessment is about 1-2 weeks.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the patient identified in step a) has a DRL corresponding to consumption ≧60 g/day of pure alcohol for men and ≧40 g/day for women.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said high URL in identified in step a) i) has been assessed by calculating mean daily alcohol consumption in g/day over a period preceding assessment, wherein said period is 1 week or longer.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said maintained DRL in step a) ii) is assessed by calculating mean daily alcohol consumption in g/day over said observation period.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said patient is subject to counseling focused on enhanced treatment adherence and reduced alcohol consumption.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said counseling is performed according to the BRENDA model.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said nalmefene is to be used for a treatment period of 6-12 months.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said patient is 12 years or older.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method according to claim 1-9, wherein the amount of nalmefene is 10-20 mg.

### Claim 11 (depends on 1)

The method according to any of claim 1, wherein said nalmefene is administered in the form of a pharmaceutically acceptable acid addition salt.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said nalmefene is administered in the form of the hydrochloride dihydrate.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said nalmefene is administered in an oral dose for that is tablets or capsules.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said nalmefene is administered in combination with a further active ingredient

### Claim 15 (depends on 1)

The method according to claim 1, wherein said patient has an alcohol use disorder.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said patient has alcohol dependence.
